On January 5, 2023, gene-editing company Metagenomi announced a $100 million Series B expansion financing co-led by Novo Holdings A/S, Catalio Capital Management, and SymBiosis. The deal was also supported by new and existing investors, including Leaps by Bayer and Moderna, as well as initial Series B leads, PFM Health Sciences and Farallon Capital Management. Wilson Sonsini Goodrich & Rosati advised Novo on the financing.
The additional funding brings the company’s total Series B earnings to $275 million, delivered by more than 30 investment groups. Metagenomi intends to use the proceeds to support major therapeutic programs from preclinical development to clinical proof of concept. The company expects to expand its pipeline and use its automated discovery engine and versatile gene-editing toolbox to specify new therapeutic targets for its proprietary gene medicine pipeline.
Novo Holdings is responsible for managing the assets of the Novo Nordisk Foundation, which aims to improve human health and social and planetary sustainability. The company invests in and manages life sciences companies.
Wilson Sonsini’s team advising on the deal includes Dan Köppen, Cassandra Castillo and Brigitte Barissy.
Please see the press release for details.